Argentina drug regulator chief admits deficiencies, vows transparency overhaul

Luis Fontana, head of Argentina's ANMAT since January, acknowledged persistent deficiencies in the agency and outlined a transformation plan to make it 'reliable and transparent' at the Amchan forum. The admission signals a potential shift in regulatory posture, though specifics on reforms and timelines remain unclear. This matters for pharmaceutical oversight and market confidence in Argentine health regulation.